Bone Biologics Corporation (BBLG)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Bone Biologics Corporation (BBLG) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Bone Biologics Corporation ever had a stock split?
Bone Biologics Corporation Profile
| Biotechnology Industry | Healthcare Sector | Jeffrey Frelick CEO | NASDAQ (CM) Exchange | 098070600 CUSIP |
| US Country | 2 Employees | - Last Dividend | 10 Jun 2025 Last Split | 31 Mar 2016 IPO Date |
Overview
Bone Biologics Corporation is a pioneering medical device company with a core focus on bone regeneration for spinal fusion, leveraging the power of recombinant human proteins. Established in 2004 and based in Burlington, Massachusetts, the company aims to address the critical need for bone healing and regeneration in various surgical specialties including spinal, orthopedic, and neurosurgery, among others. Bone Biologics has entered into a strategic license agreement with the UCLA Technology Development Group for the development and commercialization of NELL-1 for spinal fusion applications, showcasing its commitment to advancing bone regeneration technologies.
Products and Services
- NELL-1/DBM Fusion Device
This product represents the heart of Bone Biologics' offerings, focusing on enhancing spinal fusion procedures. Developed for use in skeletally mature patients suffering from degenerative disc disease at one level from L2-S1, the NELL-1/DBM Fusion Device aims to provide an advanced solution for bone regeneration. By exploiting the osteopromotive properties of the recombinant protein NELL-1 in combination with demineralized bone matrix (DBM), this device offers targeted control over bone regeneration, aiming to deliver improved surgical outcomes.
